Jumpcode Genomics

Jumpcode Genomics is a private biotechnology company based in San Diego, founded in 2017, that has developed a proprietary platform to remove 'noise' from NGS data. Its CRISPRclean technology employs programmable endonucleases to selectively deplete unwanted genomic sequences, increasing the sensitivity and reducing the cost of sequencing for critical research and diagnostic applications. The company operates as a platform tools provider, partnering with sequencing leaders and research consortia, and is in an early revenue stage as it commercializes its depletion kits. Its strategy focuses on empowering researchers in academia, biopharma, and clinical diagnostics to uncover novel biological signals previously obscured by technical limitations.

CRISPRclean platform using programmable endonuclease enzymes (e.g., CRISPR-Cas9) to deplete unwanted, abundant DNA/RNA sequences from samples prior to next-generation sequencing, thereby boosting usable data.

Jumpcode operates in a competitive niche of NGS sample preparation. Direct and indirect competitors include companies offering probe-based hybridization capture for target enrichment, alternative enzymatic depletion methods, and bioinformatics firms providing software-based background subtraction. Its key differentiator is the programmability and specificity of its CRISPR-based in vitro depletion approach, which aims for high multiplexing capability and minimal bias compared to some alternatives.